Nkarta (NKTX) has shared an update.
The Company reported promising results from its Phase 1 clinical study of NKX019, a treatment for non-Hodgkin lymphoma, showing rapid depletion of harmful B-cells followed by a healthy recovery of naïve B-cell populations in remission patients. Additionally, preliminary data indicated that two different lymphodepletion regimens preceding NKX019 treatment yielded similar pharmacokinetic profiles. These findings, while still early, suggest the potential for NKX019 to reshape immune cell profiles in patients with B-cell malignancies, offering hope for more effective treatments.
For an in-depth examination of NKTX stock, go to TipRanks’ Stock Analysis page.
